Edgewise Therapeutics’ cardiac sarcomere modulator has passed a mid-stage test in patients with a genetic heart muscle disease.
The biotech’s EDG-7500 produced “meaningful” reductions in left ventricular outflow tract gradient (LVOT-G), a measure of the ...
↧